Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
ATM deletion
Cancer:
Bladder Cancer
Drug Class:
PARP inhibitor
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Sci Adv
Title:
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
Published date:
11/22/2023
Excerpt:
...we observed a significant increase in PARP inhibitor sensitivity in all ATM-deleted cell lines compared to WT ATM parental lines...
DOI:
10.1126/sciadv.adg2263
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login